EU Commission Imposes $500 Million Fine on Teva for Patent Misuse in Multiple Sclerosis Drug Market

The European Commission has imposed a fine exceeding 460 million euros (approximately USD 500 million) on Israeli pharmaceutical company Teva. This penalty is due to Teva's alleged misuse of the patent system to extend the protection of its multiple sclerosis medication, Copaxone. The active component of this drug is glatiramer acetate. The commission accused Teva of conducting a campaign to undermine Synthon, the sole other firm with an approved drug in Europe containing this ingredient.

Representative image

Teva allegedly disseminated information that contradicted health authorities' findings, aiming to cast doubt on the safety and effectiveness of Synthon's product. The EU Commission stated that Teva targeted healthcare professionals and organisations involved in drug pricing and reimbursement. Their goal was reportedly to delay or obstruct Synthon's market entry in various countries.

Teva's Response and Appeal

In response, Teva expressed disagreement with the EU Commission's decision, describing it as "based on legal theories ... that are extreme, untested, and factually unsupported." Teva announced plans to appeal the ruling, emphasising its long-standing support for the multiple sclerosis community since 1996.

The commission highlighted that Teva's actions might have hindered potential savings for European countries. Alternative versions of the drug could be up to 80% cheaper than Copaxone. Consequently, Teva is required to pay a fine of 462.6 million euros (USD 502 million) and must avoid similar conduct in the future.

Previous Legal Challenges

In a separate case last year, Teva agreed to pay USD 225 million in the United States to resolve allegations of price-fixing related to a cholesterol-lowering medication. The US Justice Department also mandated that Teva divest its business involved in producing and selling pravastatin, a generic form of Pravachol.

The European Commission's decision underscores its commitment to ensuring fair competition within the pharmaceutical industry. By penalising practices that could restrict market access for cheaper alternatives, it aims to protect consumer interests and promote cost savings across Europe.